{"transactions":[{"id":1398521,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"ten_percent_owner":true}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"ten_percent_owner":true}}],"security":"Ordinary Shares","published_at":"2024-09-28T00:00:43.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":2660000,"price":6.05,"value":16093000.0,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the Ordinary Shares held of record by ATAI Life Sciences AG."}],"balance_after":6905774,"source":{"system":"sec-edgar","filing":"0001140361-24-042246","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816590/000114036124042246/form4.xml","form_type":"4"}},{"id":1529172,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2024-05-03T16:05:22.000Z","date":"2024-04-19","kind":"other","planned":false,"acquired":true,"reported_value":1000000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"derivative":{"exercise_price":0.185,"exercise_date":"2024-04-19","expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":5405405},"source":{"system":"sec-edgar","filing":"0000950170-24-052877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024052877/ownership.xml","form_type":"4"}},{"id":1582131,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-03-12T21:36:30.000Z","date":"2024-03-08","kind":"other","planned":false,"acquired":true,"shares":4000000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the \"Third Amendment\"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the \"Third Amendment\"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":4000000,"derivative":{"exercise_price":0.17,"exercise_date":"2024-03-08","expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1582130,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2024-03-12T21:36:30.000Z","date":"2024-03-08","kind":"other","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the \"Third Amendment\"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the \"Third Amendment\"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":9500000,"derivative":{"exercise_price":0.185,"exercise_date":"2024-03-08","expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":5405405},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1582129,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-03-12T21:36:30.000Z","date":"2023-11-28","kind":"purchase","planned":false,"acquired":true,"shares":4053750,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 28, 2023, ATAI AG purchased 750 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $750,000."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":16052850,"derivative":{"exercise_price":0.26,"exercise_date":"2023-11-28","expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":4053750},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1582128,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-03-12T21:36:30.000Z","date":"2023-11-28","kind":"purchase","planned":false,"acquired":true,"shares":750000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 28, 2023, ATAI AG purchased 750 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $750,000."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":2970000,"derivative":{"exercise_price":0.185,"exercise_date":"2023-11-28","expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":4054054},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1582127,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2024-03-12T21:36:30.000Z","date":"2023-10-06","kind":"other","planned":false,"acquired":true,"shares":8500000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 30, 2023, the Issuer, IntelGenX Corp. and ATAI Life Sciences AG (\"ATAI AG\") entered into the Second Amended and Restated Loan Agreement, which provided, among other things, for the ability for ATAI AG to convert the $8,500,000 principal amount and accrued interest under the original term loan agreement into up to 56,435,098 shares of Common Stock at a price of $0.185 per share, subject to stock exchange approval, which was obtained on October 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 30, 2023, the Issuer, IntelGenX Corp. and ATAI Life Sciences AG (\"ATAI AG\") entered into the Second Amended and Restated Loan Agreement, which provided, among other things, for the ability for ATAI AG to convert the $8,500,000 principal amount and accrued interest under the original term loan agreement into up to 56,435,098 shares of Common Stock at a price of $0.185 per share, subject to stock exchange approval, which was obtained on October 6, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":8500000,"derivative":{"exercise_price":0.185,"exercise_date":"2023-10-06","expiration_date":"2025-01-05","underlying":"Common Stock","underlying_shares":56435098},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1582126,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Option (Right to Buy)","published_at":"2024-03-12T21:36:30.000Z","date":"2023-09-30","kind":"other","planned":false,"acquired":true,"shares":7401,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each unit consists of (a) one $1,000 principal amount convertible promissory note, convertible into shares of Common Stock at $0.185, and (b) 5,405 common stock purchase warrants, at a price of $0.26 per share, at any time prior to August 31, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 30, 2023, ATAI AG entered into an amendment to a subscription agreement with the Issuer to provide ATAI AG with the right to purchase up to 7,401 additional units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 30, 2023, ATAI AG entered into an amendment to a subscription agreement with the Issuer to provide ATAI AG with the right to purchase up to 7,401 additional units."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each unit consists of (a) one $1,000 principal amount convertible promissory note, convertible into shares of Common Stock at $0.185, and (b) 5,405 common stock purchase warrants, at a price of $0.26 per share, at any time prior to August 31, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":7401,"derivative":{"exercise_date":"2023-09-30","expiration_date":"2026-08-31","underlying":"Units","underlying_shares":7401},"source":{"system":"sec-edgar","filing":"0000950170-24-030437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017024030437/ownership.xml","form_type":"4"}},{"id":1789804,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-09-05T21:00:17.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":11999100,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the convertible promissory notes and the warrants are convertible and exercisable, respectively, at the option of the holder, subject to the shareholder approval limitations, as described further in the respective documents."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"balance_after":11999100,"derivative":{"exercise_price":0.26,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":11999100},"source":{"system":"sec-edgar","filing":"0000950170-23-046540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017023046540/ownership.xml","form_type":"4"}},{"id":1789803,"issuer":{"id":91524,"kind":"organization","name":"IntelGenx Technologies Corp.","symbol":"IGXT"},"owners":[{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI","position":1,"cik":"0001840904","reported_name":"ATAI Life Sciences N.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87217,"kind":"organization","name":"ATAI Life Sciences AG","position":2,"cik":"0001776242","reported_name":"ATAI Life Sciences AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2023-09-05T21:00:17.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"reported_value":2220000,"ownership":{"direct":false,"nature":"By ATAI Life Sciences AG"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the convertible promissory notes and the warrants are convertible and exercisable, respectively, at the option of the holder, subject to the shareholder approval limitations, as described further in the respective documents."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Reflects securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein."}],"derivative":{"exercise_price":0.185,"expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":12000000},"source":{"system":"sec-edgar","filing":"0000950170-23-046540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1098880/000095017023046540/ownership.xml","form_type":"4"}}]}